Alectinib is an ATP-competitive small molecule and a second-generation inhibitor of ALK. EML4-ALK rearrangement is found in 3–5% of patients with NSCLC. The first-generation inhibitor crizotinib has changed the treatment dramatically, though most of the patients show disease progression within one year. Extra-thoracic progress, i.e., CNS metastases is common. The second-generation inhibitor alectinib has shown significant improvement in PFS and a remarkable prolongation of time to CNS progression. Alectinib has received approval as first-line therapy as well as second-line therapy after crizotinib failure. The toxicity profile is favorable compared to crizotinib and chemotherapy.
CITATION STYLE
Herden, M., & Waller, C. F. (2018). Alectinib. In Recent Results in Cancer Research (Vol. 211, pp. 247–256). Springer New York LLC. https://doi.org/10.1007/978-3-319-91442-8_17
Mendeley helps you to discover research relevant for your work.